All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

Background {#sec006}
----------

Gliomas are a type of tumor arising from glial cells. Gliomas constitute about 80% of all malignant primary brain tumors \[[@pone.0137850.ref001]--[@pone.0137850.ref002]\]. The main biochemical characteristics can provide useful information on brain tumor type and grade noninvasively \[[@pone.0137850.ref003]\]. In many studies, *in vivo* Proton Magnetic Resonance Spectroscopy, abbreviated as ^1^H-MRS, has been shown to determine tumors type and grade \[[@pone.0137850.ref004]--[@pone.0137850.ref006]\]. According to the World Health Organization (WHO) grading system, low-grade gliomas (LGG) correspond to WHO grade I-II, and high-grade gliomas (HGG) correspond to WHO grade III-IV \[[@pone.0137850.ref007]\]. Low- and high-grade gliomas differ significantly with respect to biological behavior, growth pattern, growth rate, prognosis and other attributes. Furthermore, distinct strategies are adopted in clinical treatment. Therefore, differentiating between low- and high-grade gliomas accurately is extremely important, particularly when judging the grade of pre-operative brain tumors \[[@pone.0137850.ref008]\].

At present, the main noninvasive inspection method before surgical treatment of a brain tumor is neuroimaging, of which Magnetic Resonance Imaging (MRI) is the optimal choice. A conventional MRI exam depicts a structural image of the brain, with the advantage of providing precise anatomical information about the brain tumor. Interpreting the degree of malignancy exclusively from a morphologic point of view, MRI provides little helpful biological information on other aspects of gliomas. These aspects include grade, type, boundaries with normal brain tissue, metabolic characteristics of tumoral substances, and biological behavior. A large amount of information in addition to the anatomical structure is beneficial for a more comprehensive understanding brain tumors. As a result, this type of information has gained more clinical attention and has gradually become the key to differential diagnosis and prognosis of brain tumors. As the MRI technology advances, new magnetic resonance imaging technologies such as Magnetic Resonance Spectroscopy (MRS), Diffusion-Weighted Imaging (DWI), Diffusion Tensor Imaging (DTI) and Perfusion Weighted Imaging (PWI) have emerged, providing us with new approaches for recognizing, diagnosing and classifying brain tumors. Therefore, MRS, which can measure *in vivo* brain tissue metabolism and show its biochemical information, has been widely used \[[@pone.0137850.ref009]--[@pone.0137850.ref010]\]. Thus, these techniques, particularly ^1^H-MRS, can aid in brain glioma diagnosis, differential diagnosis, grading, and classification.

Quantitative approach to multi-voxel ^1^H-MRS {#sec007}
---------------------------------------------

Many studies have shown that the type and grade of brain tumors is related to the concentration of certain metabolite components \[[@pone.0137850.ref011]--[@pone.0137850.ref013]\]. The typical quantitative indicators of magnetic resonance spectroscopy observation are Choline (Cho), N-Acetyl Aspartate (NAA), Creatine (Cr), Lactate (Lac), Lipid (Lip) and other observational data which are all biochemical metabolites from brain tissue. When a brain tumor appears, the contents of these biochemical metabolites vary in a regular manner. By determining the regular patterns, then discovering metabolic properties of different types of gliomas, we can obtain some useful information for clinical prediction of gliomas. Since biomedical metabolite information is acquired through quantification of MRS data, proper and optimized quantification techniques should influence the objectivity and robustness of its result.

MRS quantification methods can be classified into time-domain and frequency-domain according to the data feature analysis method. Time-domain quantification is based on mathematical models. Since the expression of models, such as Lorentzian lineshape and Gaussian lineshape, is concise, computation can be efficient. Time-domain quantification methods are usually divided into two main classes: interactive methods and black-box methods. The former, making good use of prior knowledge, are flexible but difficult to quantify automatically. Black-box methods limit imposing prior knowledge for simplicity, thus improving the accuracy, and are also difficult. VARPRO \[[@pone.0137850.ref014]\] is the first widely used interactive quantification method. AMARES \[[@pone.0137850.ref015]\] later performed better in terms of robustness and flexibility. HLSVD \[[@pone.0137850.ref016]\] is a well-known black-box method with many variants. QUEST \[[@pone.0137850.ref017]--[@pone.0137850.ref018]\] is implemented in the software package jMRUI-3.0 (<http://www.mrui.uab.es/mrui/>), using linear fitting to quantify on the basis of a set of metabolite signals. Because of the poor signal to noise ratio of clinical ^1^H-MRS data, the advantage of some complex methods such as QUEST on accuracy is not clear.

The frequency-domain quantification is more intuitive and straightforward. Integrating the spectrum directly is convenient, but the overlap of some metabolite component peaks *in vivo* and unsatisfactory baseline correction may lead to large error. Therefore, quantification based on model fitting \[[@pone.0137850.ref019]\] is used more widely *in vivo*. Generally these methods assume that the real part of the spectrum fits Lorentzian, Gaussian or Voigt lineshape and that the baseline can be approximated as polynomials or splines. TLS \[[@pone.0137850.ref020]\] is just one representative of these methods, as is the LCModel \[[@pone.0137850.ref021]\]. The LCModel is similar to QUEST, fitting the spectrum to a linear combination of the metabolite basis set \[[@pone.0137850.ref022]\]. After considering the set as prior knowledge, results become more precise and need more time resources.

The Chemical Shift Imaging (CSI) technique can provide multi-voxel MRS in one examination, which results in much larger amounts of data to process. Some interactive quantification methods for Single Voxel Spectroscopy (SVS) such as AMARES, burdens the user with a large quantity of repetitive and unpleasant work. Furthermore, the quantitative result is difficult to reproduce because of differences in users' prior knowledge and their state. Therefore, automated quantification is required to replace the interactive quantification with a more efficient and robust method.

In this paper, we present a new automated quantitative approach based on a convex envelope (AQoCE). This approach can be considered as a simulation of manual fitting, which can ensure efficiency and robustness, as well as give reasonably accurate results. AQoCE is a black-box method, so lacking physical meaning is still inevitable. To evaluate the performance of this new quantitative technique in grading the diagnosis of brain gliomas, AQoCE was applied to analyze the MRS data from 78 glioma cases acquired before brain tumor surgery, then the results were compared with their pathology reports. When compared to the MRS data processing software from Siemens (Trio Tim 3.0 T MRI's workstation), our AQoCE approach provides results with higher specificity and sensitivity on these samples.

Materials and Methods {#sec008}
=====================

Materials {#sec009}
---------

This research was approved by the medical ethics committee of Beijing Tian Tan Hospital, Capital Medical University. Written informed consent of each adult patient (participants) was obtained, and the written informed consents of the three minor patients' guardian completed on behalf of the minor participants were also obtained. Data were obtained from 78 cases, including 48 males (10--73 years: average age, 44.71 years); 30 females (22--68 years: average age, 43.37 years), male/female, 1.6:1; all of the cases have been confirmed by pathology. All cases (n = 78) were classified into two groups: 1) 36 cases of low-grade gliomas (LGG, WHO I-II), including 18 astrocytoma, 5 oligodendroglioma, 12 oligdendro-astrocytoma, and 1 mixed neuro-glioma; and 2) 42 cases of high-grade gliomas (HGG, WHO III-IV), including 10 anaplastic oligdendro-astrocytoma, 7 astrocytoma, 24 glioblastoma, and 1 gliomatosis cerebri. All participants underwent non-contrast and contrast MRI and non-contrast MRS before surgery. See details in [Table 1](#pone.0137850.t001){ref-type="table"}.

10.1371/journal.pone.0137850.t001

###### Pathology data.

![](pone.0137850.t001){#pone.0137850.t001g}

  No.   Gender   Age   Position of glioma                                           Type                                 WHO
  ----- -------- ----- ------------------------------------------------------------ ------------------------------------ -----
  1     F        22    right temporal lobe                                          astrocytoma                          II
  2     M        46    left temporal lobe                                           astrocytoma                          II
  3     F        31    right frontal lobe                                           astrocytoma                          II
  4     M        23    left thalamus                                                astrocytoma                          II
  5     M        55    left temporal lobe                                           astrocytoma                          II
  6     F        22    left parietal lobe                                           astrocytoma                          II
  7     M        35    left frontal lobe                                            astrocytoma                          II
  8     F        36    left temporal lobe                                           astrocytoma                          II
  9     M        55    right frontal lobe                                           astrocytoma                          II
  10    M        33    right frontal lobe                                           astrocytoma                          II
  11    M        59    left insular lobe                                            astrocytoma                          II
  12    M        10    right frontal lobe                                           astrocytoma                          II
  13    M        56    right frontal-temporal lobe                                  astrocytoma                          II
  14    M        61    right frontal-temporal lobe                                  astrocytoma                          II
  15    F        40    bilateral frontal-parietal-occipital lobe                    astrocytoma                          II
  16    F        36    left frontal-temporal lobe                                   astrocytoma                          II
  17    M        13    right basal ganglia                                          astrocytoma                          II
  18    M        19    left frontal lobe/left basal ganglia and septum pellucidum   astrocytoma                          II
  19    M        14    right frontal lobe                                           mixed glioma/neuronal tumor          II
  20    M        50    left frontal lobe                                            oligodendro-astrocytoma              II
  21    M        32    left frontal lobe                                            oligodendro-astrocytoma              II
  22    M        42    right frontal lobe                                           oligodendro-astrocytoma              II
  23    F        38    right frontal lobe                                           oligodendro-astrocytoma              II
  24    M        35    right frontal lobe                                           oligodendro-astrocytoma              II
  25    M        38    left parietal-occipital lobe                                 oligodendro-astrocytoma              II
  26    M        27    left temporal lobe                                           oligodendro-astrocytoma              II
  27    F        46    right frontal-temporal lobe                                  oligodendro-astrocytoma              II
  28    M        41    left temporal-parietal lobe                                  oligodendro-astrocytoma              II
  29    M        65    left temporal lobe                                           oligodendro-astrocytoma              II
  30    M        34    left temporal lobe                                           oligodendro-astrocytoma              II
  31    M        41    bilateral frontal-parietal lobe                              oligodendro-astrocytoma              II
  32    F        48    left parietal lobe                                           oligodendroglioma                    II
  33    M        44    right frontal lobe                                           oligodendroglioma                    II
  34    M        43    left frontal lobe                                            oligodendroglioma                    II
  35    M        40    right frontal-parietal lobe                                  oligodendroglioma                    II
  36    M        56    right frontal lobe                                           oligodendroglioma                    II
  37    F        45    right frontal-insular lobe                                   anaplastic oligodendro-astrocytoma   III
  38    F        58    left frontal-insular lobe                                    anaplastic oligodendro-astrocytoma   III
  39    F        24    right parietal lobe/corpus callosum                          anaplastic oligodendro-astrocytoma   III
  40    M        40    right frontal-insular lobe                                   anaplastic oligodendro-astrocytoma   III
  41    F        29    right frontal lobe                                           anaplastic oligodendro-astrocytoma   III
  42    M        58    left insular lobe                                            anaplastic oligodendro-astrocytoma   III
  43    F        23    corpus callosum and bilateral frontal-parietal lobe          anaplastic oligodendro-astrocytoma   III
  44    F        55    right thalamus                                               anaplastic oligodendro-astrocytoma   III
  45    F        40    left frontal lobe                                            anaplastic oligodendro-astrocytoma   III
  46    M        63    bilateral frontal lobe and corpus callosum                   anaplastic oligodendro-astrocytoma   III
  47    M        54    left temporal lobe                                           astrocytoma                          III
  48    F        53    right frontal lobe and bilateral temporal lobe               astrocytoma                          III
  49    M        44    right parietal lobe                                          astrocytoma                          III
  50    F        42    right temporal lobe                                          astrocytoma                          III
  51    F        54    left temporal lobe                                           astrocytoma                          III
  52    M        33    right temporal lobe                                          astrocytoma                          III
  53    F        52    left thalamus                                                astrocytoma                          III
  54    M        34    the third ventricle                                          glioblastoma                         III
  55    F        68    right frontal-insular lobe                                   glioblastoma                         IV
  56    M        63    left frontal lobe                                            glioblastoma                         IV
  57    M        64    left parietal-occipital lobe                                 glioblastoma                         IV
  58    F        44    right parietal-occipital lobe                                glioblastoma                         IV
  59    M        40    left temporal lobe                                           glioblastoma                         IV
  60    M        48    left frontal-temporal-insular lobe                           glioblastoma                         IV
  61    F        48    right parietal lobe                                          glioblastoma                         IV
  62    F        57    left temporal lobe                                           glioblastoma                         IV
  63    M        73    left frontal lobe                                            glioblastoma                         IV
  64    F        62    left parietal lobe                                           glioblastoma                         IV
  65    M        53    left frontal lobe                                            glioblastoma                         IV
  66    M        64    right temporal-parietal lobe                                 glioblastoma                         IV
  67    M        64    left parietal-occipital lobe                                 glioblastoma                         IV
  68    M        49    left parietal lobe/corpus callosum                           glioblastoma                         IV
  69    M        52    bilateral frontal lobe and the knee of corpus callosum       glioblastoma                         IV
  70    F        45    right frontal lobe                                           glioblastoma                         IV
  71    M        60    right parietal-occipital lobe                                glioblastoma                         IV
  72    F        57    left temporal-parietal lobe                                  glioblastoma                         IV
  73    M        25    left temporal lobe and left basal ganglia                    glioblastoma                         IV
  74    M        27    left temporal-occipital lobe                                 glioblastoma                         IV
  75    F        40    right occipital lobe                                         glioblastoma                         IV
  76    F        64    left parietal lobe                                           glioblastoma                         IV
  77    M        71    right temporal lobe                                          glioblastoma                         IV
  78    F        22    right frontal lobe                                           gliomatosis cerebri                  IV

The scanning parameters of the Siemens 3.0T MR system (Siemens, Germany) were set as follows: gradient field = 40 mT/m, switching rate = 200 T/ms.

T1-weighted: TR = 2 000 ms, TE = 9.8 ms, thickness = 5 mm, space = 6 mm, number of slices = 24, field of view (FOV) = 220×220 mm, each slice has 256×256 pixels.

T2-weighted: TR = 4 500 ms, TE = 84 ms, thickness = 5mm, space = 6 mm, number of slices = 24, FOV = 220×220 mm, each slice has 384×384 pixels.

FLAIR: TR = 7 000ms, TI = 200 ms, TE = 97 ms, thickness = 5 mm, space = 6 mm, number of slices = 24.

MRS: using head coil, 3D multi-voxel chemical shift imaging MRS method, point resolved selective spectroscopy (PRESS) technique, as well as chemical shift selecting saturation (CHESS). TR = 1 700 ms, TE = 30 ms, flip angle = 90 degrees, thickness = 20 mm, volume of interest (VOI) = 80 mm x 80 mm x 20 mm, and one MRS voxel should be 10 mm x 10 mm x 20 mm.

Procedure of the AQoCE approach {#sec010}
-------------------------------

### A) Pre-processing {#sec011}

The original MRS data consists of two parts: one is header information, which consists of patient information and attributes of spectroscopy such as size of the CSI matrix, vector of position, and length of raw signals. The other is raw signal data in time domain. In this step, we first denoise the raw signal by apodization, then obtain the spectrum of the denoised signal by Fast Fourier Transformation (FFT).

### B) Convex-envelope based baseline fitting {#sec012}

In the spectrum, the signal intensity of water is often several orders of magnitude larger than the signal intensities of other metabolite components. The residual water peak tails are often considered as an additional baseline with fluctuation. It is usually assumed that the baseline is a very smooth curve and each metabolite component peak is in a narrow range, so the baseline can be approximated by a piecewise linear curve. In this study we chose the convex envelope for fitting.

Let *f*{*n*} denote a certain range of the whole spectrum, *h*{*n*} is the convex envelope of *f*{*n*}, *k* is the length of *f*{*n*}, and *h*{*n*}. *h*{*n*} should be the maximum of a sequence set which has the property *g*{*n*} as described in [Eq (1)](#pone.0137850.e001){ref-type="disp-formula"}.

![](pone.0137850.e001.jpg){#pone.0137850.e001g}
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The convex envelope sequence *h*{*n*} is generated as follows:

Let *h* ~*i*~{*n*} denote the convex envelope of the first *i+2* points of *f*{*n*}, *I* ~*i*~{*n*} is the index set of all points in *h* ~*i*~{*n*}. Initialize *i* to be 1, then we have $$h_{1}\left\{ n \right\} = \left\{ {f\left( 1 \right),f\left( 2 \right),f\left( 3 \right)} \right\},\text{  }I_{1}\left\{ n \right\} = \left\{ {1,2,3} \right\}$$

Check if the following inequality is held or not: $$h_{i}(k - 2)\left( {I_{i}(k) - I_{i}(k - 1)} \right) + h_{i}(k)\left( {I_{i}(k - 1) - I_{i}(k - 2)} \right) > h_{i}(k - 1)\left( {I_{i}(k) - I_{i}(k - 2)} \right)$$ Where *k* is the length of *h* ~*i*~{*n*}. If the inequality is not held, remove point *h* ~*i*~(*k−*1) and its index *I* ~*i*~(*k−*1) from *h* ~*i*~{*n*} and *I* ~*i*~{*n*}, respectively. As a result, the length of *h* ~*i*~{*n*} and *I* ~*i*~{*n*} is reduced by 1. Then check the inequality again until it is held.

If *i* +2 = *k*, *h* ~*i*~{*n*} is already the convex envelope of *f*{*n*}. Go to step *d*. If *i* +2 \< *k*, then initialize *h* ~*i+1*~{*n*} and *I* ~*i+1*~{*n*} as [Eq (4)](#pone.0137850.e004){ref-type="disp-formula"} and increase *i* by 1. Go back to step *b* to make sure of the convex property.
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Restore removed points by linear interpolation, and the generation of the convex envelope sequence is complete.

### C) Bias correction {#sec013}

Use the method described in B) to generate the convex envelope for NAA (2.0ppm ± 0.5ppm), which is one of the most significant metabolite component, that we model on only one peak for simplicity and robustness, then subtract the convex envelope from the spectrum, and the maximum point in this range can be regarded as the actual position of the NAA peak. Shift the spectrum so that the actual position of the NAA peak is located at 2.02ppm. This is the aligned spectrum.

### D) Sectional baseline removal {#sec014}

Because ranges of some metabolite components were overlapping, we generated the convex envelopes for three sections. These sections are 4.3 ppm to 3.2 ppm (Cho), 3.9 ppm (Glx) to 2.0 ppm (NAA), 3.0 ppm (Cr) to 1.5 ppm, and 1.7 ppm to 1.0 ppm. Let *h* ~*1*~(*x*), *h* ~*2*~(*x*), *h* ~*3*~(*x*) and *h* ~*4*~(*x*) be their convex envelopes. Then we define the whole baseline approximation *h*(*x*) as: $$h(x) = \left\{ \begin{matrix}
{h_{1}(x)\quad 4.3 \geq x > 3.9} \\
{\text{min}(h_{1}(x),h_{2}(x))\quad 3.9 \geq x > 3.2} \\
{h_{2}(x)\quad 3.2 \geq x > 3.0} \\
{\text{min}(h_{2}(x),h_{3}(x))\quad 3.0 \geq x > 2.0} \\
\begin{array}{l}
{\text{\quad\quad  }h_{3}(x)\quad 2.0 \geq x > 1.7} \\
{\text{min}(h_{3}(x),h_{4}(x))\quad 1.7 \geq x > 1.5} \\
{\text{\quad\quad  }h_{4}(x)\quad 1.5 \geq x > 1.0} \\
\end{array} \\
\end{matrix} \right.$$

Subtracting *h*(*x*) from the aligned spectrum, the residual spectrum becomes meaningful and clear.

### E) Metabolite peak detection {#sec015}

In the range of theoretical position ±0.1ppm for every metabolite component of interest, take the maximum point as the peak value.

As this approach only requires a linear scan of the spectrum which makes it run in linear time, we can efficiently analyze a multi-voxel spectrum and obtain a metabolite component peak value.

Method of analysis of metabolite components {#sec016}
-------------------------------------------

### A) ROI selection {#sec017}

For each case, two neuroimaging experts with years of experience made the following selections:

Determine the location of the CSI slice. Normally, it is the one slice of an axial image which has a maximum volume of tumor.

Put three regions of interest (ROI) in the enhanced tumoral area, peritumoral area which is about 1 cm from tumor margins, and contralateral areas distant to the tumor.

In each ROI, choose 1\~3 MRS voxels to measure according to the tumor size.

Use the average to reduce the error. Finally, normalize the results of the two experts and also obtain the average.

### B) Relative quantitative calculation of metabolites {#sec018}

The metabolites Cho, NAA, Cr, and sum of Lipid and Lac (Lip-Lac, LL) were acquired in short TE spectrum. The raw data were processed using two methods: the convex-envelope based automated quantitative approach (AQoCE) and Siemens MRS data processing software ([Fig 1](#pone.0137850.g001){ref-type="fig"}). Metabolic ratios (Cho/NAA, Cho/Cr and LL/Cr) were used in the statistical analysis. For reasons of quantification errors in 29/78 of Siemens LL results by modeling ([Fig 2](#pone.0137850.g002){ref-type="fig"}), and no quantification error in AQoCE LL results by taking the maximum, only the ratio of LL/Cr calculated by AQoCE is used.

![Images of a 31-year-old female with a grade II astrocytoma.\
MRS grid map overlaid on a T2-weighted image (top left). T1-weighted image (top right). Spectroscopy processed by the AQoCE approach (bottom left). Spectroscopy processed by Siemens processing software (bottom right). The chosen spectroscopy volume of interest (VOI) is located in the peritumoral area. Scale bar: 1 cm.](pone.0137850.g001){#pone.0137850.g001}

![Samples of spectroscopy processed by Siemens processing software with LL quantification error.\
All the chosen spectroscopies belong to tumoral area. The quantification results are presented in red line, and these errors should be found at the location of Lac point by comparing with original spectrum (white line).](pone.0137850.g002){#pone.0137850.g002}

### C) Statistical analysis {#sec019}

Our design for statistical tests is presented here. All statistical tests are two-sided, performed with SPSS19.0 (SPSS Inc., Chicago, IL). *p* values less than 0.05 were considered statistically significant.

First, an independent sample *t*-test was used for evaluating significant difference between the metabolic ratios in high- and low-grade gliomas, including Cho/NAA, Cho/Cr and LL/Cr.

Second, in order to determine the sensitivity and specificity of AQoCE, post-processing methods were used for identifying glioma grade and the receiver operating characteristic curve (ROC). To determine the metabolites which could be significant as diagnostic indicators, Cho/Cr, Cho/NAA and LL/Cr were chosen. Furthermore, logistic regression which combines these ratios, provided better predictive value.

Third, as the data distribution was skewed, the Kruskal-Wallis test followed by all pairwise multiple comparisons was used for evaluating the significance between the affected (tumoral, peritumoral area) and contralateral area.

Results {#sec020}
=======

In this study, the default MRS data processing software, run on a Siemens Trio Tim 3.0T MRI's workstation, was selected as a reference approach and was called "Siemens" in the present study. "Siemens" was used to evaluate the performance of the proposed AQoCE method. Both AQoCE and "Siemens" were used to analyze all 78 cases, including 36 cases of LGG and 42 cases of HGG: 18 astrocytoma (WHO II), 5 oligdendroglioma (WHO II), 12 oligdendro-astrocytoma (WHO II), 1 mixed neuro-glioma (WHO II), 10 anaplastic oligdendro-astrocytoma (WHO III), 7 astrocytoma (WHO III), 24 glioblastoma (WHO IV), 1 gliomatosis cerebri (WHO IV). The results are as follows.

First, ^1^H-MRS is valuable in the clinical diagnosis and prognosis (by identifying the glioma grade). Gliomas consist of abnormal glial cells proliferation. During growth, tumor cells infiltrate and push normal neurons, resulting in a slight decrease in Cr and NAA, a significant increase in Cho, and an appearance of Lac and Lipid \[[@pone.0137850.ref023]\], as both approaches demonstrate. In our study, the AQoCE approach demonstrates that the ratios of Cho/NAA, Cho/Cr and LL/Cr are significantly different between LGG and HGG (*p* = 0.005, *p* = 0.002 and *p* = 0.001, respectively). The "Siemens" approach demonstrates only that the Cho/Cr ratio shows a significant difference (*p* = 0.007). Brain tumor ratios of Cho/NAA, Cho/Cr and LL/Cr are positively correlated with brain glioma grading. They can help to differentiate high- from low-grade gliomas, which is in agreement with other reports \[[@pone.0137850.ref024]\]. Details are shown in Tables [2](#pone.0137850.t002){ref-type="table"} and [3](#pone.0137850.t003){ref-type="table"}.

10.1371/journal.pone.0137850.t002

###### Statistics of intratumoral metabolic ratios by AQoCE and Siemens approaches.

![](pone.0137850.t002){#pone.0137850.t002g}

  approach      low-grade gliomas (LGG)   high-grade gliomas (HGG)                                       
  ------------- ------------------------- -------------------------- ----------- ----------- ----------- -----------
  **Siemens**   0.95±0.58                 1.31±0.49                  \-          1.12±0.56   2.59±2.87   \-
  **AQoCE**     1.04±0.43                 1.27±0.31                  1.07±1.32   1.35±0.50   1.70±0.76   2.65±2.51

Note: Data are expressed as mean±standard deviation.

10.1371/journal.pone.0137850.t003

###### *t*-test of intratumoral metabolic ratios in AQoCE and Siemens approaches.

![](pone.0137850.t003){#pone.0137850.t003g}

  approach      Cho/NAA       Cho/Cr        LL/Cr
  ------------- ------------- ------------- -------------
  **Siemens**   1.314/0.193   2.841/0.007   \-
  **AQoCE**     2.870/0.005   3.251/0.002   3.552/0.001

Note: Data are *t*/*p* values of independent sample *t*-test.

Second, the ROC curve demonstrates that the AQoCE approach predicts the grade of gliomas by combining Cho/NAA, Cho/Cr and LL/Cr in the tumoral area with good performance. The logistic regression formula used for combination of metabolic ratios is: $$probabilities\  = 1/\left\lbrack {1 + e^{- {({- a\text{  } + \, b\, \times \text{  Cho}/\text{Cr  } + \text{  }c\text{  } \times \text{  Cho}/\text{NAA~+~}d\text{  } \times \text{  LL}/\text{Cr}})}}}\operatorname{} \right..$$

*a* = 4.733, *b* = 1.580, *c* = 1.290, *d* = 0.698 are obtained by fitting to the results of AQoCE approach. The best diagnostic cut-off point for the probabilities of logistic regression is 0.376. In this setting, the AQoCE approach achieves a sensitivity of 92.9%, a specificity of 72.2%, and an area under the ROC curve (AUC) of 0.860. While fitting to the results of "Siemens" approach, *a* = 3.168, *b* = 1.902, *c* = 0.252 are obtained. The best cut-off point is 0.446, with a sensitivity of 78.6%, a specificity of 75.0%, and an AUC of 0.806. The ratio of Cho/NAA achieves little for the prediction because it shows no significant difference in "Siemens" approach. See [Table 4](#pone.0137850.t004){ref-type="table"} for details.

10.1371/journal.pone.0137850.t004

###### Results of intratumoral ROC using the AQoCE and Siemens approaches.

![](pone.0137850.t004){#pone.0137850.t004g}

  ----------------- ------------------- --------------------- --------------------- ---------
  **AQoCE**         **cut-off point**   **Sensitivity (%)**   **Specificity (%)**   **AUC**
  **Cho/NAA**       1.118               69.0                  66.7                  0.687
  **Cho/Cr**        1.339               81.0                  63.9                  0.774
  **LL/Cr**         1.728               61.9                  91.7                  0.802
  **combination**   0.376               92.9                  72.2                  0.860
  **Siemens**       **cut-off point**   **Sensitivity (%)**   **Specificity (%)**   **AUC**
  **Cho/NAA**       0.902               66.7                  61.1                  0.616
  **Cho/Cr**        1.422               78.6                  75.0                  0.803
  **combination**   0.446               78.6                  75.0                  0.806
  ----------------- ------------------- --------------------- --------------------- ---------

Note: The combination of metabolic ratios is established by the logistic regression formula. AUC: Area Under Curve.

Third, in theory, along with a sort order from tumoral area to peritumoral area and contralateral area, both Cho/NAA and Cho/Cr ratios show a regular variation from high to low. In this study, we analyzed the Cho/NAA and Cho/Cr in the tumoral area, peritumoral area and contralateral area. The results show that both Cho/NAA and Cho/Cr in the AQoCE approach demonstrates a significant difference, with *p*≤0.019 between all three areas. For the "Siemens" approach, the ratios Cho/NAA and Cho/Cr demonstrate a significant difference only between the tumor and other areas. In this respect, the AQoCE approach is more sensitive with the tumor margin region. Results are shown in Tables [5](#pone.0137850.t005){ref-type="table"} and [6](#pone.0137850.t006){ref-type="table"}.

10.1371/journal.pone.0137850.t005

###### Statistics of metabolic ratios in different areas using AQoCE and Siemens approaches.

![](pone.0137850.t005){#pone.0137850.t005g}

                intratumor   peritumor   contra lateral areas                           
  ------------- ------------ ----------- ---------------------- ----------- ----------- -----------
  **Siemens**   1.04±0.57    2.00±2.21   0.54±0.24              0.97±0.23   0.45±0.18   0.87±0.21
  **AQoCE**     1.21±0.49    1.50±0.63   0.59±0.16              0.95±0.16   0.47±0.11   0.84±0.16

Note: Data are expressed as mean±standard deviation.

10.1371/journal.pone.0137850.t006

###### Kruskal-Wallis test of metabolic ratios in different areas using AQoCE and Siemens approaches.

![](pone.0137850.t006){#pone.0137850.t006g}

                intratumor / peritumor   intratumor / contra lateral areas   peritumor / contra lateral areas                                
  ------------- ------------------------ ----------------------------------- ---------------------------------- -------------- ------------- -------------
  **Siemens**   6.946/0.000              7.009/0.000                         9.107/0.000                        9.313/0.000    2.161/0.092   2.304/0.064
  **AQoCE**     7.824/0.000              7.683/0.000                         11.526/0.000                       10.405/0.000   3.702/0.001   2.722/0.019

Note: Data are *h*/*p* values of the Kruskal-Wallis test.

Discussion {#sec021}
==========

An overview of the recent literatures on brain tumor diagnosis using an *in vivo* ^1^H-MRS quantitative method shows that most authors presented the statistical analysis results for tumor type-specific or for tumor grading based on ^1^H-MRS quantitative results using MRI application software provided by GE, Siemens and Philips \[[@pone.0137850.ref025]--[@pone.0137850.ref032]\]. Their various results imply that although ^1^H-MRS can be used as an auxiliary tool for brain tumor diagnosis, the MRS data processing methods are not robust enough for *in vivo* complex tissues. For example, model-based methods such as HLSVD are perfect for phantom data, but not sufficient for *in vivo* glioma data \[[@pone.0137850.ref033]\]. This means that the MRS quantitative approach is crucial for obtaining the content of metabolites, which can directly impact the accuracy of diagnosis. This is particularly true for the method of residual water removal, baseline estimation and metabolite quantification.

The process of the "Siemens" reference approach includes water suppression, filtering, filling zero, Fourier transformation, frequency correction, phase correction, baseline correction and curve fitting, with a total of 8 steps. In contrast, the process of the AQoCE approach includes apodization and Fourier transformation, convex-envelope based baseline fitting, bias correction, sectional baseline removal, peak detection and modelization, 5 steps in all. The main innovation is the convex-envelope based baseline fitting method, taking the lower enveloping curve as baseline which is achieved by feature-point extraction and linear interpolation.

This study highlights some advantages of AQoCE:

1.  Versatile: No specific parameter is needed in advance and the metabolic components of *in vivo* and complex tissues can be better represented, due to the assumption that the tails of residual water fit the convex envelope curve.

2.  Efficient: Much faster runtime than many existing methods. It takes only a few seconds to process one patient's data by AQoCE, while an example of HLSVD exam takes minutes.

3.  Significant: The quantitative results are statistically significant for separating three types of voxels (tumoral, peritumoral area and contralateral area) and in distinguishing between LGG and HGG.

Moreover, the proposed analysis method of metabolic components, including ROI selection, relative quantitative calculation of metabolites, and statistical methods of analysis is reasonable and valid.

As current research reports on glioma grading show, MRS quantitative analysis may be the simplest, safest, and most effective method. However, the accuracy is not as high as the combination analysis of MRS and PWI \[[@pone.0137850.ref032], [@pone.0137850.ref034]--[@pone.0137850.ref036]\].

There are still some limitations to this study. First, the sample size is not large enough to cover all types and grades of tumors and samples are heterogeneous in terms of WHO grade, which lessens statistical power. We cannot completely rule out the possibility of changes in results when the sample size increases. In the future, we will increase sample size and complete clinical data. Second, choosing ROI accurately and reasonably can greatly impact the metabolites. This process should be more formally established to avoid errors. Third, some important metabolites have not been taken into account, such as myo-Inositol (mI) \[[@pone.0137850.ref037]\]. It would be of value to analyze their characteristics and evaluate their diagnostic value based on obtained metabolic data in order to improve the diagnostic and prognosis accuracy for gliomas. Finally, apply the new approach on combinations with other new magnetic resonance imaging technologies such as PWI, for higher specificity and sensitivity in glioma screening \[[@pone.0137850.ref038]--[@pone.0137850.ref039]\].

An automated CSI data processing software that implements AQoCE is shown in [S1](#pone.0137850.s001){ref-type="supplementary-material"}--[S3](#pone.0137850.s003){ref-type="supplementary-material"} Figs. The user only needs to load CSI raw data acquired by the Siemens MR system (with the extension of.rda) and click on any voxel of interest or select any number of voxel of interest, then all of the selected multi-voxel MRS results, both wave form and peak value will be immediately displayed in a new window.

Conclusions {#sec022}
===========

In this work, we propose a new automated quantitative approach based on a convex envelope (AQoCE) and apply it to multi-voxel ^1^H-MRS analysis. Under the limited clinical data used, this approach can efficiently evaluate brain glioma grading and demonstrate characteristics of brain glioma metabolism. It can also suggest the presence of peritumoral area infiltration. AQoCE has been integrated into our MRS data processing software and will be available as a free download on the following website: <http://mdpslab.voog.com/softwares>.

Supporting Information {#sec023}
======================

###### Plot view mode of the MRS processing software.

One or multiple spectroscopies are shown in right window.

(TIF)

###### 

Click here for additional data file.

###### Grid view mode of the MRS processing software.

Multiple grids of spectroscopy can be chosen by mouse drag. Thumbnail of spectroscopy is shown in right window.

(TIF)

###### 

Click here for additional data file.

###### Spectrogram view mode of the MRS processing software.

Multiple grids of metabolic ratios can be chosen by mouse drag and drop. Color bar is used as the indication of the ratio intensity.

(TIF)

###### 

Click here for additional data file.

###### Pathology information and data acquired by AQoCE & Siemens approach.

All the data used in the statistical analysis is included in the file.

(XLSX)

###### 

Click here for additional data file.
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